Earnings Call Summary | Cutera(CUTR.US) Q2 2024 Earnings Conference
Earnings Call Summary | Cutera(CUTR.US) Q2 2024 Earnings Conference
Non-GAAP loss from operations for Q2 2024 was $21.3 million.The following is a summary of the Cutera, Inc (CUTR) Q2 2024 Earnings Call Transcript:
以下是古特拉公司（Cutera, Inc）2024年第二季度业绩会议呼叫记录摘要：
Financial Performance:
金融业绩：
Q2 2024 revenue was $34.4 million, down from $61.8 million in Q2 2023, a 44% decrease year-over-year.
Non-GAAP gross profit for Q2 2024 was $9.6 million, with a gross margin rate of 28.8%.
Non-GAAP loss from operations for Q2 2024 was $21.3 million.
Cutera provided revised full-year revenue guidance to $140 million to $145 million from a prior range of $160 million to $170 million.
2024年第二季度营业收入为3440万美元，较2023年第二季度的6180万美元下降44%。
2024年第二季度非通用会计原则毛利润为960万美元，毛利率为28.8%。
2024年第二季度非通用会计原则运营亏损2130万美元。
古特拉公司修订全年营业收入指引至1.4亿至1.45亿美元，之前为1.6亿至1.7亿美元的区间。
Business Progress:
业务进展：
International launch of AviClear was successful, with over 70 systems sold outside of North America.
New capital sales organization structure implemented in North America.
Partnership established with L'Oreal's SkinCeuticals business in Japan, expected to launch in Q4 2024.
AviClear国际推出非常成功，在北美以外销售了超过70套系统。
在北美实施了新的资本销售组织结构。
与L'Oreal的SkinCeuticals业务在日本建立合作关系，预计于2024年第四季度推出。
Opportunities:
机会：
The international success of AviClear and restructuring in North America present opportunities for growth and improved sales productivity.
The new partnership with L'Oreal's SkinCeuticals in Japan represents potential growth in skincare.
AviClear在国际上的成功和北美的重组为公司的增长和销售生产率的提高带来了机会。
与L'Oreal公司的SkinCeuticals在日本建立的新合作关系代表着皮肤护理业务的潜在增长。
Risks:
风险：
Continued macroeconomic pressures affecting capital equipment revenue, particularly in North America.
High sales force turnover in North America impacting short-term revenue.
持续存在的宏观经济压力对资本设备营收产生影响，尤其是在北美。
北美销售团队的高流失率对短期营收产生影响。
More details: Cutera IR
更多详情请参见古特拉公司（Cutera）投资者关系页面。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。